Molecular changes associated with the development of resistance to imatinib in an imatinib-sensitive canine neoplastic mast cell line carrying a KIT c.1523A>T mutation

European Journal of Haematology

Volumn 95, Issue 6, 2015, Pages 524-531

  Kobayashi, Masato ^a   Kuroki, Shiori ^a   Tanaka, Yu ^a   Moriya, Yukari ^a   Kozutumi, Yukari ^a   Uehara, Yuji ^a   Ono, Kenichiro ^a,b   Tamura, Kyoichi ^a   Washizu, Tsukimi ^a   Bonkobara, Makoto ^a  

^a NIPPON VETERINARY AND LIFE SCIENCE UNIVERSITY   (Japan)

^b Japan Animal Referral Medical Center   (Japan)

Author keywords

KIT; Dog; Imatinib; Neoplastic mast cells; Resistance

Indexed keywords

DASATINIB; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; STEM CELL FACTOR; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; STAT3 PROTEIN; STEM CELL FACTOR RECEPTOR;

ANIMAL CELL; ARTICLE; CANCER CELL LINE; CANCER RESISTANCE; CANINE NEOPLASTIC MAST CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE MUTATION; MAST CELL; NONHUMAN; ONCOGENE C KIT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECOMBINANT GENE; ANIMAL; CELL PROLIFERATION; DISEASE MODEL; DNA MUTATIONAL ANALYSIS; DOG; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; MASTOCYTOSIS; METABOLISM; MUTATION; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DNA MUTATIONAL ANALYSIS; DOGS; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; IMATINIB MESYLATE; MASTOCYTOSIS; MUTATION; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-KIT; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84955370581     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12526     Document Type: Article

References (31)

1. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007;37:435-53.
2. Orfao A, Garcia-Montero AC, Sanchez L, Escribano L. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007;138:12-30.
3. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006;108:2366-72.
4. Bodemer C, Hermine O, Palmérini F, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 2010;130:804-15.
5. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093-103.
6. Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quintás-Cardama A, Luthra R, Kantarjian HM, Verstovsek S. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 2009;33:1481-4.
7. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004;103:3222-5.
8. Zhang LY, Smith ML, Schultheis B, Fitzgibbon J, Lister TA, Melo JV, Cross NC, Cavenagh JD. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006;30:373-8.
9. Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 2008;14:2717-25.
10. Hoffmann KM, Moser A, Lohse P, Winkler A, Binder B, Sovinz P, Lackner H, Schwinger W, Benesch M, Urban C. Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation. Blood 2008;112:1655-7.
11. Mital A, Piskorz A, Lewandowski K, Wasag B, Limon J, Hellmann A. A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. Eur J Haematol 2011;86:531-5.
12. Morren MA, Hoppé A, Renard M, Debiec RM, Uyttebroeck A, Dubreuil P, Martin L. Imatinib mesylate in the treatment of diffuse cutaneous mastocytosis. J Pediatr 2013;162:205-7.
13. Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NC, Tefferi A. Imatinib for systemic mast-cell disease. Lancet 2003;362:535-6.
14. Pagano L, Valentini CG, Caira M, et al. Advanced mast cell disease: an Italian Hematological Multicenter experience. Int J Hematol 2008;88:483-8.
15. Valentini CG, Rondoni M, Pogliani EM, et al. Mast cell leukemia: a report of ten cases. Ann Hematol 2008;87:505-8.
16. Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 2009;84:790-4.
17. Jung AG, Horny HP, Sotlar K, Overbeck T, Schön MP, Ippert U. Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis. J Am Acad Dermatol 2011;65:224-6.
18. Ma HB, Xu X, Liu WP, Chang H, Zeng F, Wang YC. Successful treatment of mast cell sarcoma of the uterus with imatinib. Int J Hematol 2011;94:491-4.
19. Alvarez-Twose I, González P, Morgado JM, Jara-Acevedo M, Sánchez-Muñoz L, Matito A, Mollejo M, Orfao A, Escribano L. Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis. J Clin Oncol 2012;30:126-9.
20. Agarwala MK, George R, Mathews V, Balasubramanian P, Thomas M, Nair S. Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report. J Dermatolog Treat 2013;24:481-3.
21. Takahashi T, Kitani S, Nagase M, Mochizuki M, Nishimura R, Morita Y, Sasaki N. IgG-mediated histamine release from canine mastocytoma-derived cells. Int Arch Allergy Immunol 2001;125:228-35.
22. Takeuchi Y, Fujino Y, Fukushima K, Watanabe M, Nakagawa T, Ohno K, Sasaki N, Sugano S, Tsujimoto H. Biological effect of tyrosine kinase inhibitors on three canine mast cell tumor cell lines with various KIT statuses. J Vet Pharmacol Ther 2012;35:97-104.
23. Takeuchi Y, Fujino Y, Watanabe M, Nakagawa T, Ohno K, Sasaki N, Sugano S, Tsujimoto H. Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines. Vet Immunol Immunopathol 2010;137:208-16.
24. Yamada O, Kobayashi M, Sugisaki O, et al. Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation. Vet Immunol Immunopathol 2011;142:101-6.
25. Isotani M, Yamada O, Lachowicz JL, Tamura K, Yagihara H, Fujino Y, Ono K, Washizu T, Bonkobara M. Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours. Br J Haematol 2010;148:144-53.
26. Foster R, Griffith R, Ferrao P, Ashman L. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase. J Mol Graph Model 2004;23:139-52.
27. Rossi F, Yozgat Y, de Stanchina E, Veach D, Clarkson B, Manova K, Giancotti FG, Antonescu CR, Besmer P. Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib. Mol Cancer Res 2010;8:1271-83.
28. Takahashi T, Serada S, Ako M, et al. New findings of kinase switching in gastrointestinal stromal tumor under imatinib using phosphoproteomic analysis. Int J Cancer 2013;133:2737-43.
29. Lennartsson J, Blume-Jensen P, Hermanson M, Pontén E, Carlberg M, Rönnstrand L. Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction. Oncogene 1999;18:5546-53.
30. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, Mirosevich J, Lee FY, Jove R. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005;65:9185-9.
31. Bolós V, Gasent JM, López-Tarruella S, Grande E. The dual kinase complex FAK-Src as a promising therapeutic target in cancer. Onco Targets Ther 2010;24:83-97.